| Overview |
| bs-5553R-A647 |
| PARK2(Ser378) Polyclonal Antibody, ALEXA FLUOR® 647 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Pig, Guinea Pig |
| Specifications |
| ALEXA FLUOR® 647 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human PARK2 around the phosphorylation site of Ser378 |
| Ser378 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5071 |
| Cytoplasm, Nucleus, Cell membrane |
| PARK2phospho S378; AR JP; E3 ubiquitin protein ligase parkin; FRA6E; LPRS 2; LPRS2; PARK 2; PARK2; Parkinson disease autosomal recessive juvenile 2; Parkinson disease protein 2; Parkinson juvenile disease protein 2; PDJ; PRKN 2; PRKN; PRKN2; Ubiquitin E3 ligase PRKN. |
| Parkinson's Disease, the second most common neurodegenerative disease after Alzheimer's Disease, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha synuclein and parkin inclusions). Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin. Parkin, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz